- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-428, Nivolumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
- Interventions
- Motexafin Gadolinium
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia
- Interventions
- PRT543
- Drug
- Lead sponsor
- Prelude Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • San Francisco, California • Newark, Delaware + 19 more
- Conditions
- Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- JNJ-74699157
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- AFP464, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Neoplasms
- Interventions
- Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
- Conditions
- Advanced Solid Tumors That Are MTAP Deficient
- Interventions
- AZD3470, Datopotamab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more
- Conditions
- Advanced Solid Malignancies
- Interventions
- MLN0128
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 11 more
- Conditions
- Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pegylated liposomal doxorubicin hydrochloride, PSC 833
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Solid Tumor, Adult
- Interventions
- ADA-011, PD(L)-1 inhibitor
- Drug
- Lead sponsor
- Adanate, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Orlando, Florida • Durham, North Carolina + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine hydrochloride, tipifarnib
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
- Interventions
- AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more
- Conditions
- Neoplasms, Lymphoma, Hematologic Neoplasms
- Interventions
- TAK-981
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- La Jolla, California • Boston, Massachusetts • Detroit, Michigan + 5 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pelitinib, temsirolimus
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Solid Tumors
- Interventions
- IMC-1121B, 1121B
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumors
- Interventions
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 5
- States / cities
- La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- AZD4360
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Providence, Rhode Island • Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- AZD7789
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Solid Neoplasm
- Interventions
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- CP-868,596, Docetaxel, AG-013736
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- docetaxel, irinotecan hydrochloride
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Stamford, Connecticut
- Conditions
- Advanced Solid Tumours
- Interventions
- EBC-129, Pembrolizumab
- Drug
- Lead sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas
- Conditions
- Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
- Interventions
- AZD8835, AZD8835 in combination with fulvestrant
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Greenville, South Carolina • Nashville, Tennessee + 2 more